BlueWillow News and Announcements

BlueWillow Biologics to Present Significant Progress on Its Novel Intranasal Vaccine Technology at World Vaccine Congress Europe

October 28, 2024

Presentation will demonstrate safety and immunogenicity, provide an update on NIH-funded bird flu trial, and highlight the technology’s potential in pandemic preparedness.

Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice

December 15, 2022

Ganesan S, Acosta H, Brigolin C, Orange K,…

BlueWillow Announces Promising Results for Intranasal Covid-19 Booster Vaccine

March 2, 2022

https://www.businesswire.com/news/home/20220302005134/en/Bl…

BlueWillow Biologics Presents Positive Interim Anthrax Phase 1 Data to BARDA

November 3, 2021

ANN ARBOR, Mich.--(BUSINESS WIRE)--BlueWillow Biologics, Inc. today…

BlueWillow Biologics Names Leading Viral Infectious Disease Experts to Scientific Advisory Board

September 21, 2021

BlueWillow Biologics, Inc., a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, today announced the formation of the Company's Scientific Advisory Board (SAB) with three leading viral infectious disease experts. The SAB will provide strategic and scientific counsel to BlueWillow’s clinical programs.

BlueWillow Biologics Announces Positive Interim Results from Phase 1 Trial of Intranasal Anthrax Vaccine

August 24, 2021

BlueWillow Biologics, Inc., a privately held clinical-stage…

Medigen and BlueWillow Biologics Partner to Develop Intranasal Vaccine for SARS-CoV-2

November 10, 2020

Research indicates that intranasal administration is effective…

BlueWillow Receives FDA Clearance to Begin Phase 1 Study of its Intranasal Anthrax Vaccine

October 23, 2019

BlueWillow Biologics today announced the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug application for the company’s next-generation anthrax vaccine candidate. The Phase 1 clinical study is expected to begin enrollment in late 2019.

BlueWillow Awarded NIH Contract to Advance Development of its Therapeutic Peanut Allergy Vaccine

October 1, 2019

BlueWillow Biologics^®, a clinical-stage biopharmaceutical company, has been awarded a Fast Track Small Business Research Innovation contract from the National Institute of Allergy and Infectious Diseases for development of an intranasal therapeutic peanut allergy vaccine.

BlueWillow Biologics Named to Crain’s ‘Cool Places to Work in Michigan’

August 6, 2019

BlueWillow Biologics^® today announced the company has been recognized as one of the 2019 “Cool Places to Work in Michigan” by Crain’s Detroit.

BlueWillow Biologics Awarded Patent for Intranasal Genital Herpes Vaccine

July 23, 2019

BlueWillow Biologics^® today announced the issuance of U.S. patent number 10,206,996 to BlueWillow for the development of an intranasal NanoVax^® herpes simplex virus (HSV) vaccine.

BlueWillow Biologics Announces Issuance of Intranasal Anthrax Vaccine Patent

May 29, 2019

BlueWillow Biologics^® today announced the issuance of U.S. patent number 10,138,279 covering an intranasal NanoVax^® anthrax vaccine.

BlueWillow Biologics Awarded Grant for Chlamydia Vaccine Development

September 26, 2018

BlueWillow Biologics^® today announced the company has been awarded an NIH Small Business Innovation Research (SBIR) grant for the development of an intranasal NanoVax^® vaccine for the prevention of chlamydia.

BlueWillow Biologics Announces Issuance of Therapeutic Cancer Vaccine Patent

May 30, 2018

BlueWillow announces the issuance of a patent to the University of Michigan, under exclusive license to BlueWillow, which allows use of BlueWillow’s NanoVax^® platform with tumor antigens to create novel therapeutic vaccines that could potentially generate immune responses to treat existing cancers.

NanoBio Announces Corporate Name Change to BlueWillow Biologics and Closes $10M Series A Financing

May 7, 2018

NanoBio Corporation, a clinical-stage biopharmaceutical company, today announced that it has changed its corporate name to BlueWillow Biologics^® in conjunction with the closing of a $10 million Series A financing. The financing round was led by North Coast Technology Investors, Line Moon Ventures and the University of Michigan through its MINTS initiative.